van der Voort, Anna http://orcid.org/0000-0003-2016-1971
van der Hoogt, Kay J. J.
Wessels, Ronni
Schipper, Robert-Jan
Wesseling, Jelle
Sonke, Gabe S.
Mann, Ritse M.
Article History
Received: 15 October 2023
Revised: 15 April 2024
Accepted: 26 April 2024
First Online: 5 July 2024
Change Date: 13 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00330-024-11008-8
Compliance with ethical standards
:
: The scientific guarantor of this publication is R.M. Mann.
: R.M. Mann received research funding for studies unrelated to this work from: Siemens Healthineers, Bayer healthcare, Beckton & Dickinson, Screenpoint medical, Koning, PA Imaging. R.M. Mann is advisory editorial board member of <i>European Radiology</i>, associate editor for breast imaging of Radiology and member of the executive board of the European Society of Breast Imaging (EUSOBI). G.S. Sonke received institutional research funding from AstraZeneca, Merck, Novartis, Roche and Seagen and consulting fees from Biovica and Seagen, all unrelated to this work. All other authors declare no competing interests.
: M. Lopez-Yurda kindly provided statistical advice for this manuscript.
: Written informed consent was waived by the Institutional Review Board.
: The Institutional Review Board approval from the Review Board of the Netherlands Cancer Institute was obtained.
: A subset of 45 patients have been previously reported in Van Ramshorst MS, Loo CE, Groen EJ et al (2017) MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 164:99-106. .
: